BMAL1 depletion enhances the sensitivity of adrenocortical carcinoma cells to DNA damage-based therapies both in vitro and in vivo, implicating BMAL1 as a potential target in cancer therapeutics [90]. Here, BMAL1 is linked to adrenal cortex carcinoma.